TY - JOUR
T1 - Urine gastrin-releasing peptide in the first week correlates with bronchopulmonary dysplasia and post-prematurity respiratory disease
AU - Voynow, Judith A.
AU - Fisher, Kimberley
AU - Sunday, Mary E.
AU - Cotten, Charles M.
AU - Hamvas, Aaron
AU - Hendricks-Muñoz, Karen D.
AU - Poindexter, Brenda B.
AU - Pryhuber, Gloria S.
AU - Ren, Clement L.
AU - Ryan, Rita M.
AU - Sharp, Jack K.
AU - Young, Sarah P.
AU - Zhang, Haoyue
AU - Greenberg, Rachel G.
AU - Herring, Amy H.
AU - Davis, Stephanie D.
N1 - Funding Information:
The authors would like to acknowledge the critical work of the PROP Site and Data Coordinating Center Investigators and research staff, the support of Lynn Taussig, MD, University of Arizona, and of Carol J. Blaisdell, MD, Division of Lung Diseases, National Heart, Lung, and Blood Institute, NIH, Bethesda, MD for their guidance. The authors express their indebtedness to the generosity of our NICU families who consented to this and other research studies. This study was supported by NIH grants: 5R01 HL105702 (Duke University, Indiana University, Virginia Commonwealth University, Cincinnati Children's Hospital Medical Center), U01 HL101813 (University of Rochester and University at Buffalo), U01 HL101465 (Washington University), U01 HL101800 (Cincinnati Children's Hospital Medical Center), and U01 HL101794 (University of Pennsylvania).
Funding Information:
The authors would like to acknowledge the critical work of the PROP Site and Data Coordinating Center Investigators and research staff, the support of Lynn Taussig, MD, University of Arizona, and of Carol J. Blaisdell, MD, Division of Lung Diseases, National Heart, Lung, and Blood Institute, NIH, Bethesda, MD for their guidance. The authors express their indebtedness to the generosity of our NICU families who consented to this and other research studies. This study was supported by NIH grants: 5R01 HL105702 (Duke University, Indiana University, Virginia Commonwealth University, Cincinnati Children's Hospital Medical Center), U01 HL101813 (University of Rochester and University at Buffalo), U01 HL101465 (Washington University), U01 HL101800 (Cincinnati Children's Hospital Medical Center), and U01 HL101794 (University of Pennsylvania).
Publisher Copyright:
© 2020 Wiley Periodicals, Inc.
PY - 2020/4/1
Y1 - 2020/4/1
N2 - Rationale: Bronchopulmonary dysplasia (BPD) is associated with post-prematurity respiratory disease (PRD) in survivors of extreme preterm birth. Identifying early biomarkers that correlate with later development of BPD and PRD may provide insights for intervention. In a preterm baboon model, elevated gastrin-releasing peptide (GRP) is associated with BPD, and GRP inhibition mitigates BPD occurrence. Objective: We performed a prospective cohort study to investigate whether urine GRP levels obtained in the first postnatal week were associated with BPD, PRD, and other urinary biomarkers of oxidative stress. Methods: Extremely low gestational age infants (23-28 completed weeks) were enrolled in a US multicenter observational study, The Prematurity and Respiratory Outcomes Program (http://clinicaltrials.gov/ct2/show/NCT01435187). We used multivariable logistic regression to examine the association between urine GRP in the first postnatal week and multiple respiratory outcomes: BPD, defined as supplemental oxygen use at 36 + 0 weeks postmenstrual age, and post-PRD, defined by positive quarterly surveys for increased medical utilization over the first year (PRD score). Results: A total of 109 of 257 (42%) infants had BPD, and 120 of 217 (55%) had PRD. On adjusted analysis, GRP level more than 80 was associated with BPD (adjusted odds ratio [aOR], 1.83; 95% confidence interval [CI], 1.03-3.25) and positive PRD score (aOR, 2.46; 95% CI, 1.35-4.48). Urine GRP levels correlated with duration of NICU ventilatory and oxygen support and with biomarkers of oxidative stress: allantoin and 8-hydroxydeoxyguanosine. Conclusions: Urine GRP in the first postnatal week was associated with concurrent urine biomarkers of oxidative stress and with later diagnoses of BPD and PRD.
AB - Rationale: Bronchopulmonary dysplasia (BPD) is associated with post-prematurity respiratory disease (PRD) in survivors of extreme preterm birth. Identifying early biomarkers that correlate with later development of BPD and PRD may provide insights for intervention. In a preterm baboon model, elevated gastrin-releasing peptide (GRP) is associated with BPD, and GRP inhibition mitigates BPD occurrence. Objective: We performed a prospective cohort study to investigate whether urine GRP levels obtained in the first postnatal week were associated with BPD, PRD, and other urinary biomarkers of oxidative stress. Methods: Extremely low gestational age infants (23-28 completed weeks) were enrolled in a US multicenter observational study, The Prematurity and Respiratory Outcomes Program (http://clinicaltrials.gov/ct2/show/NCT01435187). We used multivariable logistic regression to examine the association between urine GRP in the first postnatal week and multiple respiratory outcomes: BPD, defined as supplemental oxygen use at 36 + 0 weeks postmenstrual age, and post-PRD, defined by positive quarterly surveys for increased medical utilization over the first year (PRD score). Results: A total of 109 of 257 (42%) infants had BPD, and 120 of 217 (55%) had PRD. On adjusted analysis, GRP level more than 80 was associated with BPD (adjusted odds ratio [aOR], 1.83; 95% confidence interval [CI], 1.03-3.25) and positive PRD score (aOR, 2.46; 95% CI, 1.35-4.48). Urine GRP levels correlated with duration of NICU ventilatory and oxygen support and with biomarkers of oxidative stress: allantoin and 8-hydroxydeoxyguanosine. Conclusions: Urine GRP in the first postnatal week was associated with concurrent urine biomarkers of oxidative stress and with later diagnoses of BPD and PRD.
KW - bronchopulmonary dysplasia
KW - gastrin-releasing peptide
KW - reactive oxygen species
UR - http://www.scopus.com/inward/record.url?scp=85078676469&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85078676469&partnerID=8YFLogxK
U2 - 10.1002/ppul.24665
DO - 10.1002/ppul.24665
M3 - Article
C2 - 31995668
AN - SCOPUS:85078676469
SN - 8755-6863
VL - 55
SP - 899
EP - 908
JO - Pediatric Pulmonology
JF - Pediatric Pulmonology
IS - 4
ER -